Correlation of preoperative plasma levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer

Urology

Volumn 61, Issue 2, 2003, Pages 359-364

  Shariat, Shahrokh F ^a   Kim, Jahong ^a   Nguyen, Cuong ^a   Wheeler, Thomas M ^a   Lerner, Seth P ^a,b   Slawin, Kevin M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REGULATOR PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER MODEL; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL EXAMINATION; CONTROLLED STUDY; CYSTECTOMY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BLADDER; BLADDER TUMOR; BLOOD; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; PROSTATE TUMOR; STATISTICS; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0037289762     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02253-7     Document Type: Article

References (28)

1. Lerner SP, and Skinner DG: Radical cystectomy for bladder cancer, in Vogelzang NJ, Shipley WU, Scardino PT, et al (Eds): Comprehensive Textbook of Genitourinary Oncology. Philadelphia, Williams & Wilkins, 2000, vol 2, pp 425-447.
2. Lerner S.P., Skinner D.G., Lieskovsky G., et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases long-term results . J Urol. 149:1993;758-765.
3. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer long-term results in 1,054 patients . J Clin Oncol. 19:2001;666-675.
4. Shariat S.F., Kim J.H., Andrews B., et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 92:2001;2985-2992.
5. Andrews B., Shariat S.F., Kim J.H., et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 167:2002;1475-1481.
6. Gohji K., Fujimoto N., Komiyama T., et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 78:1996;2379-2387.
7. Gohji K., Nomi M., Niitani Y., et al. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 18:2000;2963-2971.
8. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 272:1997;12181-12188.
9. Hoeflich A., Fettscher O., Lahm H., et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 60:2000;834-838.
10. Chatterjee S, and Singh P: Anti-IGFBP-2 suppresses prostate tumor growth in nude mice. A975. Programs and Abstracts of the 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000.
11. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
12. Ayabe T., Tsutsumi O., Sakai H., et al. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocrin J. 44:1997;419-424.
13. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk a case-control analysis . J Natl Cancer Inst. 91:1999;151-156.
14. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 91:1999;620-625.
15. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk a prospective study . Science. 279:1998;563-566.
16. Iwamura M., Ishibe M., Sluss P.M., et al. Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines. Urol Res. 21:1993;27-32.
17. Sun H.Z., Wu S.F., Tu Z.H. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res. 11:2001;107-115.
18. Dunn S.E., Kari F.W., French J., et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53- deficient mice. Cancer Res. 57:1997;4667-4672.
19. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 276:1996;1309-1315.
20. Shariat S.F., Bergamaschi F., Adler H.L., et al. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 56:2000;423-429.
21. Wheeler T.M., Dillioglugil O., Kattan M.W., et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 29:1998;856-862.
22. Shariat S.F., Lamb D.J., Kattan M.W., et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:2002;833-841.
23. Katsaros D., Yu H., Levesque M.A., et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer. 37:2001;478-485.
24. Petridou E., Skalkidou A., Dessypris N., et al. Insulin-like growth factor binding protein-3 predicts survival from acute childhood leukemia. Oncology. 60:2001;252-257.
25. Helle S.I., Holly J.M., Tally M., et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer. 69:1996;335-339.
26. Butt A.J., Firth S.M., Baxter R.C. The IGF axis and programmed cell death. Immunol Cell Biol. 77:1999;256-262.
27. Rajah R., Katz L., Nunn S., et al. Insulin-like growth factor binding protein (IGFBP) proteases functional regulators of cell growth . Prog Growth Factor Res. 6:1995;273-284.
28. Frost V.J., Helle S.I., Lonning P.E., et al. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab. 81:1996;2216-2221.